EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische StudieOpen Access · CC BY 4.0

Phase 3 THOR Japanese subgroup analysis: erdafitinib in advanced or metastatic urothelial cancer and fibroblast growth factor receptor alterations

Nobuaki Matsubara, Yuji Miura, Hiroyuki Nishiyama, Rikiya Taoka, Takahiro Kojima, Nobuaki Shimizu, Jason Hwang, Tatsuya Ote, Ryo Oyama, Kiichiro Toyoizumi, Sutapa Mukhopadhyay, Spyros Triantos und 2 weitere

International Journal of Clinical Oncology · 2024

DOI: 10.1007/s10147-024-02583-3 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift International Journal of Clinical Oncology, 2024. Verfasst von Nobuaki Matsubara und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan. nmatsuba@east.ncc.go.jp. Hauptthemen laut MEDLINE: Quinoxalines. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Janssen Pharmaceutical K.K..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

In the THOR trial (NCT03390504) Cohort 1, erdafitinib demonstrated significantly prolonged overall survival (OS) (median 12.1 versus 7.8 months) and reduced risk of death by 36% (hazard ratio 0.64, P = 0.005) compared with chemotherapy in metastatic urothelial carcinoma (mUC) patients with FGFR alterations who progressed after ≥ 1 prior treatments, including anti-PD-(L)1. There have been no reports of the Japanese subgroup results yet.

Methods

THOR Cohort 1 randomized patients to erdafitinib once daily or docetaxel/vinflunine once every 3 weeks. Primary endpoint was OS. Secondary endpoints included progression-free survival (PFS) and objective response rate (ORR). No specific statistical power was set for this Japanese subgroup analysis.

Results

Of 266 patients randomized, 27 (14 erdafitinib; 13 chemotherapy) were Japanese. Baseline characteristics were generally similar between treatments and to the overall population, except for more males, lower body weight, and more upper tract primary tumors among Japanese patients. Compared with chemotherapy, erdafitinib showed improved OS (median 25.4 versus 12.4 months), PFS (median 8.4 versus 2.9 months) and ORR (57.1% versus 15.4%). Any grade treatment-related adverse events (AEs) occurred in all patients from both arms but Grade 3/4 AEs and AEs leading to discontinuation were lower in the erdafitinib arm. No new safety signals were observed in the Japanese subgroup.

Conclusion

In the Japanese subgroup, erdafitinib showed improved survival and response compared to chemotherapy, with no new safety concerns. These results support erdafitinib as a treatment option for Japanese mUC patients with FGFR alterations, and early FGFR testing after diagnosis of mUC should be considered.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

QuinoxalinesHumansMaleFemaleAgedMiddle AgedAged, 80 and overPyrazolesUrologic NeoplasmsReceptors, Fibroblast Growth FactorJapanProgression-Free SurvivalAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Transitional CellAdultUrinary Bladder NeoplasmsMutationEast Asian People

Stichwörter der Autor:innen

ErdafitinibFibroblast growth factor receptorJapanese subgroupMetastatic urothelial carcinomaOral tyrosine kinase inhibitor

Substanzen

erdafitinibQuinoxalinesPyrazolesReceptors, Fibroblast Growth Factor

Autor:innen und Institutionen

  • Department of Medical Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan. nmatsuba@east.ncc.go.jp.
  • Department of Medical Oncology, Toranomon Hospital, 2-2-2 Toranomon, Minato-ku, Tokyo, 105-8470, Japan.
  • Department of Urology, Institute of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki, 305-8575, Japan.
  • Department of Urology, Faculty of Medicine, Kagawa University, 1750-1 Ikenobe, Miki-cho, Kita-gun, Kagawa, 761-0793, Japan.
  • Department of Urology, Aichi Cancer Center Hospital, 1-1 Kanokoden, Chikusa-ku, Nagoya, Aichi, 464-8681, Japan.
  • Department of Urology, Gunma Prefectural Cancer Center, 3-39-22 Showa-machi, Maebashi, Gunma, 371-8511, Japan.

Förderung

  • Janssen Pharmaceutical K.K.

Zitieren

APA

Matsubara, N., Miura, Y., Nishiyama, H., Taoka, R., Kojima, T., Shimizu, N., Hwang, J., Ote, T., Oyama, R., Toyoizumi, K., Mukhopadhyay, S., Triantos, S., Deprince, K., & Loriot, Y. (2024). Phase 3 THOR Japanese subgroup analysis: erdafitinib in advanced or metastatic urothelial cancer and fibroblast growth factor receptor alterations. International Journal of Clinical Oncology. https://doi.org/10.1007/s10147-024-02583-3

Vancouver

Matsubara N, Miura Y, Nishiyama H, Taoka R, Kojima T, Shimizu N, et al. Phase 3 THOR Japanese subgroup analysis: erdafitinib in advanced or metastatic urothelial cancer and fibroblast growth factor receptor alterations. International Journal of Clinical Oncology. 2024. doi:10.1007/s10147-024-02583-3

BibTeX
@article{Matsubara2024,
  author = {Matsubara, Nobuaki and Miura, Yuji and Nishiyama, Hiroyuki and Taoka, Rikiya and Kojima, Takahiro and Shimizu, Nobuaki and Hwang, Jason and Ote, Tatsuya and Oyama, Ryo and Toyoizumi, Kiichiro and Mukhopadhyay, Sutapa and Triantos, Spyros and Deprince, Kris and Loriot, Yohann},
  title = {Phase 3 THOR Japanese subgroup analysis: erdafitinib in advanced or metastatic urothelial cancer and fibroblast growth factor receptor alterations},
  journal = {International Journal of Clinical Oncology},
  year = {2024},
  doi = {10.1007/s10147-024-02583-3}
}
Kostenlos starten →